CD44 and ovarian cancer: In the current study, we studied the efficiency of siRNA delivery of MDR1 siRNA loaded HA-PEI/HA-PEG CD44 targeted nanoparticles and their effects on circumventing drug resistance in an MDR ovarian cancer model in vitro and in vivo.